Literature DB >> 16084654

Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons.

G Wotherspoon1, A Fox, P McIntyre, S Colley, S Bevan, J Winter.   

Abstract

We have localized cannabinoid receptor 2 protein in rat and mouse somatic sensory nervous system, using an antibody that recognizes mouse cannabinoid receptor 2. Little or no cannabinoid receptor 2 immunoreactivity was found in sections of naive rat or mouse dorsal root ganglia or spinal cord. This was in accord with the lack of detectable cannabinoid receptor 2 mRNA in (dorsal root ganglion) neurons by in situ hybridization experiments described in the literature. However, we could detect cannabinoid receptor 2 immunoreactivity following unilateral nerve damage-either by sciatic nerve section, or by spinal nerve ligation. It was localized to the superficial laminae of the dorsal horn of the spinal cord, ipsilateral to the nerve damage, coincident with the area of termination of damaged afferents which was marked by loss of isolectin B4 binding. This upregulation was not seen in cannabinoid receptor 2 null mice. The cannabinoid receptor 2 protein in spinal cord appeared to be expressed on sensory neuron afferent terminals as it colocalized with two markers of damaged afferents, namely growth associated protein-43 and the neuropeptide galanin. Moreover, it did not colocalize with markers of activated microglial cells (OX-42) or astroglial cells (glial fibrillary acidic protein) in rat spinal cord. In the peripheral nerve, accumulation of cannabinoid receptor 2 immunoreactivity was seen in nerve sections proximal, but not distal, to the ligation site, suggesting transport down the nerve from the cell bodies. Although convincing cannabinoid receptor 2 immunoreactivity was seen in neither uninjured nor injured dorsal root ganglion neuron cell bodies in tissue sections, expression was detectable in isolated, cultured neurons that had received a prior axotomy in vivo. This clear demonstration of CB(2) receptors on sensory neurons suggests an additional cellular target for CB(2) agonist induced analgesia, at least in neuropathic models.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16084654     DOI: 10.1016/j.neuroscience.2005.06.009

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  104 in total

1.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

Review 2.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.

Authors:  Alysia N Lozano-Ondoua; Courtney Wright; Anna Vardanyan; Tamara King; Tally M Largent-Milnes; Mark Nelson; Juan Miguel Jimenez-Andrade; Patrick W Mantyh; Todd W Vanderah
Journal:  Life Sci       Date:  2010-02-20       Impact factor: 5.037

5.  Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands.

Authors:  Brady K Atwood; James Wager-Miller; Christopher Haskins; Alex Straiker; Ken Mackie
Journal:  Mol Pharmacol       Date:  2011-11-07       Impact factor: 4.436

6.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

Authors:  E J Rahn; A Makriyannis; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 7.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.

Authors:  J Guindon; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

8.  Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.

Authors:  Farinaz Nasirinezhad; Stanislava Jergova; James P Pearson; Jacqueline Sagen
Journal:  Neuropharmacology       Date:  2014-12-05       Impact factor: 5.250

9.  Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.

Authors:  Matteo Gianella-Borradori; Ivy Christou; Carole J R Bataille; Rebecca L Cross; Graham M Wynne; David R Greaves; Angela J Russell
Journal:  Bioorg Med Chem       Date:  2014-11-08       Impact factor: 3.641

10.  Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.

Authors:  Elizabeth J Rahn; Alexander M Zvonok; Ganesh A Thakur; Atmaram D Khanolkar; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2008-07-29       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.